论文部分内容阅读
随着机会感染的增加,象β-内酰胺类和氨基甙类等具有强抗菌力和杀菌作用的新抗生素的研究正在迅速发展。抗生素是由微生物产生的,其衍生物大部分是微生物代谢产物经化学改建而得。随着有机合成化学的发展,人们正在研究合成具有高活性的新衍生物。另一方面,依据新的筛选方法及新的产药菌生产法,正继续努力开发新的抗菌物质。一个新抗生素的开发,要应用细胞工程、遗传工程等微生物学、有机化学的新技术,进行临床前动物实验,检验其有效性、毒性及吸收排泄等药动学性质以及临床研究等几个阶段,需要数年或十数年的时间,所以要准确地叙述抗生素发展的新动向是很困难的。本文只简单介绍化学疗法学会对临床研究结果所报告的一些研究动向。由于引起感染细菌的变化,以往抗生素难
With the increase of opportunistic infections, the research of new antibiotics such as β-lactams and aminoglycosides with strong antibacterial and bactericidal activity is rapidly developing. Antibiotics are produced by microorganisms, most of which derive their chemical metabolites from microbial metabolites. With the development of organic synthesis chemistry, people are studying the synthesis of new derivatives with high activity. On the other hand, efforts are being made to develop new antibacterial substances based on the new screening method and the new drug-producing bacteria method. The development of a new antibiotic, the application of cell engineering, genetic engineering and other microbiology, new technologies of organic chemistry, pre-clinical animal experiments to test its effectiveness, toxicity and absorption of excretion and other pharmacokinetic properties and clinical research in several stages , It takes several years or ten years, so it is very difficult to accurately describe the new trend of antibiotic development. This article only briefly describes some of the trends reported by the Society of Chemotherapy in clinical research. Antibiotics have historically been difficult due to changes that cause bacterial infections